Loading clinical trials...
Loading clinical trials...
Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Renal Impairment and Normal Renal Function
Conditions
Interventions
NNC0194-0499
Locations
1
Germany
Novo Nordisk Investigational Site
Berlin, Germany
Start Date
February 15, 2023
Primary Completion Date
November 10, 2023
Completion Date
November 10, 2023
Last Updated
December 6, 2023
NCT03151473
NCT02754037
NCT06168383
NCT05989711
NCT00666016
NCT02653300
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions